Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

ClinicalTrials.gov ID: NCT00240253

Public ClinicalTrials.gov record NCT00240253. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.

Study identification

NCT ID
NCT00240253
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
AstraZeneca
Industry
Enrollment
200 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2005
Primary completion
May 31, 2006
Completion
May 31, 2006
Last update posted
Mar 30, 2015

2005 – 2006

United States locations

U.S. sites
34
U.S. states
24
U.S. cities
34
Facility City State ZIP Site status
Research Site Phoenix Arizona
Research Site Concord California
Research Site La Jolla California
Research Site Los Gatos California
Research Site Salinas California
Research Site Walnut Creek California
Research Site Denver Colorado
Research Site New Britain Connecticut
Research Site Washington D.C. District of Columbia
Research Site Palm Harbor Florida
Research Site Atlanta Georgia
Research Site Indianapolis Indiana
Research Site Wichita Kansas
Research Site Lexington Kentucky
Research Site Baton Rouge Louisiana
Research Site Bloomfield Hills Michigan
Research Site Detroit Michigan
Research Site Grand Rapids Michigan
Research Site Chesterfield Missouri
Research Site Butte Montana
Research Site Omaha Nebraska
Research Site Charlotte North Carolina
Research Site Durham North Carolina
Research Site Cincinnati Ohio
Research Site Oklahoma City Oklahoma
Research Site Medford Oregon
Research Site Portland Oregon
Research Site Philadelphia Pennsylvania
Research Site Tipton Pennsylvania
Research Site Nashville Tennessee
Research Site Dallas Texas
Research Site Charlottesville Virginia
Research Site Olympia Washington
Research Site Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00240253, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 30, 2015 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00240253 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →